New therapy using vesicles from immune cells shows promise against cancer

Researchers at the University of Pennsylvania have developed a groundbreaking cancer treatment using small extracellular vesicles (sEVs) derived from natural killer (NK) cells, Techno-Science reported. These vesicles target the DR5 receptor on tumor cells, triggering apoptosis, a process where cancer cells self-destruct.

In preclinical studies on melanoma, breast, and liver cancers, sEVs significantly reduced tumor growth and improved survival in mice. The vesicles also disrupted the tumors’ immunosuppressive environment, attacking supportive cells like cancer-associated fibroblasts and enhancing the immune response by activating T lymphocytes.

Unlike personalized therapies, sEVs are easier to produce and store, offering a more accessible treatment option for a broader range of patients. Researchers are now focused on scaling up production and conducting safety studies for future clinical trials. This approach could revolutionize cancer treatment by delivering targeted, effective, and less toxic therapies to patients.